The Court pointed out the potential of the pharmaceutical dossier, while pointing out the lack of an assessment of its impact, both in terms of savings and in preventing adverse drug reactions. It also highlighted the performance of its IT system, despite certain risks to the security of personal data, and recalled that its conditions for integration into the personal medical file were not yet met. It is necessary to continue developing the pharmaceutical dossier by generalising its use, in particular in health establishments, consolidating its new functionalities and ensuring its articulation with the shared medical record and the digital health space.